Profile data is unavailable for this security.
About the company
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM).
- Revenue in USD (TTM)0.00
- Net income in USD-37.98m
- Incorporated1996
- Employees20.00
- LocationCellectar Biosciences Inc100 Campus DriveFLORHAM PARK 07932United StatesUSA
- Phone+1 (608) 441-8120
- Fax+1 (608) 441-8121
- Websitehttps://www.cellectar.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genelux Corp | 170.00k | -28.30m | 102.89m | 23.00 | -- | 5.18 | -- | 605.26 | -1.22 | -1.22 | 0.007 | 0.7389 | 0.0102 | -- | -- | 7,391.30 | -169.32 | -- | -- | -- | -- | -- | -16,645.29 | -- | -- | -6.48 | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
| Cue Biopharma Inc | 5.49m | -50.73m | 103.61m | 53.00 | -- | 2.71 | -- | 18.87 | -1.11 | -1.11 | 0.12 | 0.7855 | 0.0719 | -- | 6.26 | 103,584.90 | -66.40 | -57.45 | -81.71 | -68.41 | -- | -- | -924.10 | -810.87 | -- | -- | 0.1804 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
| Nanopharmaceutics Inc | 1.01m | -549.47k | 104.40m | 50.00 | -- | -- | -- | 103.41 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
| aTyr Pharma Inc | 588.00k | -53.93m | 109.38m | 56.00 | -- | 1.30 | -- | 186.03 | -0.9029 | -0.9029 | 0.0099 | 1.24 | 0.0047 | -- | 0.2868 | 10,500.00 | -43.13 | -45.45 | -48.85 | -52.74 | -- | -- | -9,172.11 | -784.19 | -- | -- | 0.021 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
| Inotiv Inc | 585.17m | -33.21m | 110.13m | 1.96k | -- | 0.4333 | 5.03 | 0.1882 | -1.29 | -1.29 | 22.73 | 9.85 | 0.6858 | 6.46 | 7.12 | 299,320.70 | -3.96 | -23.84 | -4.62 | -29.26 | 30.29 | 29.31 | -5.78 | -33.24 | 1.28 | 0.1431 | 0.5988 | -- | 4.52 | 85.10 | 68.80 | -- | 83.64 | -- |
| Cellectar Biosciences Inc | 0.00 | -37.98m | 110.33m | 20.00 | -- | -- | -- | -- | -3.20 | -3.20 | 0.00 | -0.0654 | 0.00 | -- | -- | 0.00 | -225.65 | -83.69 | -499.83 | -99.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -32.80 | -- | 17.55 | -- |
| Relmada Therapeutics Inc | 0.00 | -98.79m | 111.04m | 20.00 | -- | 1.30 | -- | -- | -3.28 | -3.28 | 0.00 | 2.84 | 0.00 | -- | -- | 0.00 | -78.89 | -- | -87.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| FibroGen Inc | 147.75m | -284.23m | 113.40m | 486.00 | -- | -- | -- | 0.7675 | -2.93 | -2.93 | 1.52 | -2.07 | 0.2859 | 0.4597 | 6.28 | 304,016.50 | -55.51 | -30.62 | -119.42 | -42.31 | 87.24 | 93.52 | -194.16 | -119.08 | 1.33 | -53.30 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
| DiaMedica Therapeutics Inc | 0.00 | -19.38m | 113.87m | 18.00 | -- | 2.23 | -- | -- | -0.6168 | -0.6168 | 0.00 | 1.35 | 0.00 | -- | -- | 0.00 | -43.77 | -45.38 | -46.37 | -48.24 | -- | -- | -- | -- | -- | -- | 0.00008 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
| Vigil Neuroscience Inc | 0.00 | -82.64m | 113.88m | 69.00 | -- | 0.9353 | -- | -- | -2.13 | -2.13 | 0.00 | 3.24 | 0.00 | -- | -- | 0.00 | -48.43 | -- | -51.93 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| OptiNose Inc | 70.99m | -35.48m | 114.17m | 132.00 | -- | -- | -- | 1.61 | -0.3162 | -0.3162 | 0.6329 | -0.7705 | 0.5635 | 0.9869 | 2.64 | 537,780.30 | -28.17 | -48.25 | -- | -98.95 | 87.84 | 86.96 | -49.99 | -131.66 | 0.5511 | -1.79 | 2.99 | -- | -6.93 | 58.64 | 52.58 | -- | -27.96 | -- |
| Zhong Yuan Bio-Technology Holdings Ltd | 2.49m | 232.02k | 114.92m | 35.00 | 509.80 | 453.88 | -- | 46.08 | 0.0128 | -0.0176 | 0.1395 | 0.0143 | 0.8583 | -1.61 | 3.25 | 71,253.43 | 6.49 | -- | 19.10 | -- | 106.30 | -- | 7.57 | -- | 0.8309 | 2.53 | 0.8593 | -- | -28.60 | -- | -148.37 | -- | -- | -- |
| Sangamo Therapeutics Inc | 176.23m | -257.83m | 115.33m | 405.00 | -- | 1.19 | -- | 0.6544 | -1.46 | -1.46 | 1.01 | 0.4653 | 0.4843 | -- | 76.61 | 435,140.80 | -70.85 | -26.09 | -90.72 | -31.04 | -- | -- | -146.30 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
| Hongchang International Co Ltd | 2.68m | -378.79k | 115.49m | 8.00 | -- | 2.85 | -- | 43.16 | -0.0009 | -0.0009 | 0.0071 | 0.078 | 0.1065 | -- | 2.78 | -- | -1.51 | -7.98 | -1.60 | -10.94 | 2.59 | 11.47 | -14.16 | -64.88 | 3.74 | -- | 0.1417 | -- | 3,289.22 | -- | -42.63 | -- | -- | -- |
| GlycoMimetics Inc | 10.00k | -36.90m | 117.94m | 35.00 | -- | 3.07 | -- | 11,794.42 | -0.5841 | -0.5841 | 0.0002 | 0.5966 | 0.0002 | -- | 0.0625 | 285.71 | -75.98 | -43.60 | -90.65 | -47.82 | -- | -- | -368,994.20 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
Data as of May 03 2024. Currency figures normalised to Cellectar Biosciences Inc's reporting currency: US Dollar USD
67.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AIGH Capital Management LLCas of 23 Jan 2024 | 2.66m | 21.67% |
| Adar1 Capital Management LLCas of 23 Jan 2024 | 1.82m | 14.84% |
| Nantahala Capital Management LLCas of 31 Dec 2023 | 1.35m | 10.99% |
| Worth Venture Partners LLCas of 31 Dec 2023 | 693.91k | 5.65% |
| Rosalind Advisors, Inc.as of 31 Mar 2024 | 621.48k | 5.06% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 480.71k | 3.91% |
| Acuta Capital Partners LLCas of 31 Dec 2023 | 477.50k | 3.89% |
| Geode Capital Management LLCas of 31 Dec 2023 | 68.87k | 0.56% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 57.04k | 0.46% |
| Citadel Securities LLCas of 31 Dec 2023 | 51.22k | 0.42% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
